The Study Of Expression Of Vascular Endothelial Growth Factor And Endostatin In Serum And In Bronchoalveolar Lavage Fluid In Patients With Lung Cancer

Objective To evaluate the expression of vascular endothelial growth factor (VEGF) and endostatin in bronchoalveolar lavage fluid (BALF) and serum in patients with lung cancer. And to analysis the relationship between the levels of them and clinical features as well as pathophysiological characteristics.Methods The samples of serum and BALF were obtained from 47 patients with untreated primary lung cancer and 18 patients with benign pulmonary diseases.The levels of VEGF and endostatin were analyzed by enzyme-linked immunosorbent assay (ELISA).To compare VEGF and endostatin expressions in lung cancer with in benign pulmonary diseases.Furthermore, to analysis the relationship between the levels of VEGF and endostatin and the clinical features as well as pathophysiological characteristics. After standardization with the potassium-ion levels, the relative value of VEGF and endostatin in BALF were determined as the expression parameters.Results The concentrations of VEGF and endostatin in BALF were significantly higher than that in serum both in patients with lung cancer and benign pulmonary diseases.The expression of VEGF and endostatin in serum (60.93 ± 38.23 pg/ml,131.71 ± 50.32 ng/ml)and in BALF(362.52±339.98 pg/ml, 502.56 ± 302.00 ng/ml)in patients with lung cancer was significantly higher than that in patients with benign pulmonary diseases (33.28±26.49 pg/ml, 85.86 ± 36.86 ng/ml, 168.63 ± 172.05 pg/ml and 279.49±135.17 ng/ml, respectively) (P<0.01).The levers of VEGF and endostatin in serum and BALF in advanced stage lung cancer patients were higher than that of early stage patients.Theexpression of VEGF and endostatin in serum and BALF in adenocarcinoma patients was significantly higher than that in patients with squamous cell carcinoma and SCLC.VEGF and endostatin concentrations in BALF and in serum were significantly greater in patients with lymph node and long distance metastasis than those patients with no metastasis. The index of VEGF and endostatin in central type lung cancer patients were greater than that of patients in peripheral lung cancer.However, the expressions of VEGF and endostatin in serum and BALF were not associated with the patient's gender, age and cancer locations (right vs left, or superior vs middle or inferior lobar branches).Moreover, the expressions of VEGF and endostatin in serum were closely related to that in BALF in patients with lung cancer respectively (all P=0.000).But no obvious relationship was found between VEGF and endostatin in serum or BALF.Conclusions (l)The expressions of VEGF and endostatin in serum are closely related to that in BALF in patients with lung cancer.(2)To detect of VEGF and endostatin in serum and in BALF may help to distinguish the lung cancer from benign pulmonary diseases.But it is more valuable to detect the expressions of VEGF and endostatin in BALF than in serum.(3)The gender, age and the location of cancer(right vs left, or superior vs middle or inferior lobar branches) don't affect the expressions of VEGF and endostatin in serum or BALF.But the levers of VEGF and endostatin in serum and in BALF are significantly associated with cancer stages, histoiogical types, lymph node and long distance metastasis. (4)We can reasonably expect that to detect the expressions of VEGF and endostatin in serum or in BALF may reveal the biological behaviors of lung cancer well.